Small Molecule
BOLD-100 + FOLFOX for Advanced Cancers
This trial will test the safety of a new ruthenium-based drug, BOLD-100, when combined with a standard chemotherapy regimen. The drug will be given intravenously, and the trial will first assess safety in a small group of patients before expanding to a larger group.
Popular Filters
Trials for CCA Patients
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
Small Molecule Inhibitor
TRK-950 Combinations for Ovarian Cancer
This trial is testing a new drug, TRK-950, combined with other cancer treatments in patients with advanced cancers. The goal is to see if TRK-950 can help these treatments work better by boosting the body's ability to fight cancer or making cancer cells more vulnerable.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
Trials for Bile Duct Cancer Patients
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
Small Molecule Inhibitor
TRK-950 Combinations for Ovarian Cancer
This trial is testing a new drug, TRK-950, combined with other cancer treatments in patients with advanced cancers. The goal is to see if TRK-950 can help these treatments work better by boosting the body's ability to fight cancer or making cancer cells more vulnerable.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
Trials for Metastatic Patients
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Trials for FGFR2 Positive Patients
Tyrosine Kinase Inhibitor
RLY-4008 for Bile Duct Cancer
This trial is testing a new drug called RLY-4008 in patients with hard-to-treat cancers that can't be removed by surgery or have spread. The drug works by blocking a protein that helps cancer cells grow.
Tyrosine Kinase Inhibitor
Afatinib + Pemigatinib for Solid Tumors
This trial is testing if a combination of two drugs, Afatinib and Pemigatinib, is safe and effective for treating certain types of advanced solid tumors with specific genetic mutations. The study
FGFR Inhibitor
Tinengotinib for Bile Duct Cancer
This trial is testing an oral medication called Tinengotinib for patients with a specific type of bile duct cancer that has not responded to other treatments. The medication works by blocking a protein that helps cancer cells grow. The goal is to see if Tinengotinib can slow down or stop the cancer in these patients.
Kinase Inhibitor
Pemigatinib vs Chemotherapy for Bile Duct Cancer
This trial is testing a new drug called pemigatinib against the usual cancer treatment. It focuses on patients with advanced bile duct cancer who have a specific change in their genes. The goal is to see if pemigatinib is more effective and safer than the usual treatment. Pemigatinib is the first of its kind approved in the US, receiving approval recently.
Trials for IDH Positive Patients
PARP Inhibitor
Olaparib for Advanced Cancer
This trial will study how well olaparib works in treating patients with certain types of cancer that have spread and usually cannot be controlled with treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase 3 Trials
Monoclonal Antibodies
CTX-009 + Paclitaxel for Biliary Tract Cancer
This trial tests a new drug (CTX-009) combined with chemotherapy in patients with advanced biliary tract cancers who have already had other treatments and cannot have surgery. The treatment aims to boost the immune system and stop cancer cell growth.
FGFR Inhibitor
Tinengotinib for Bile Duct Cancer
This trial is testing an oral medication called Tinengotinib for patients with a specific type of bile duct cancer that has not responded to other treatments. The medication works by blocking a protein that helps cancer cells grow. The goal is to see if Tinengotinib can slow down or stop the cancer in these patients.
Alkylating agents
Chemotherapy for Biliary Tract Cancer
This trial is testing how well two cancer-fighting drugs work together, and whether adding a third drug makes them more effective in treating patients with advanced biliary tract cancers. The drugs aim to kill cancer cells, stop them from dividing, or prevent them from spreading.
Kinase Inhibitor
Pemigatinib vs Chemotherapy for Bile Duct Cancer
This trial is testing a new drug called pemigatinib against the usual cancer treatment. It focuses on patients with advanced bile duct cancer who have a specific change in their genes. The goal is to see if pemigatinib is more effective and safer than the usual treatment. Pemigatinib is the first of its kind approved in the US, receiving approval recently.
Trials With No Placebo
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
Small Molecule Inhibitor
TRK-950 Combinations for Ovarian Cancer
This trial is testing a new drug, TRK-950, combined with other cancer treatments in patients with advanced cancers. The goal is to see if TRK-950 can help these treatments work better by boosting the body's ability to fight cancer or making cancer cells more vulnerable.
CAR T-cell Therapy
TIL Therapy for Biliary Tract Cancer
This trial uses a special chemotherapy followed by the patient's own lab-grown immune cells and a drug to boost the immune system. It targets patients with advanced biliary tract cancers, which are difficult to treat. The process involves removing tumor cells, growing immune cells in a lab, reducing the patient's existing immune cells, and then infusing the lab-grown cells back into the patient.
View More Related Trials
Frequently Asked Questions
Introduction to cholangiocarcinoma
What are the top hospitals conducting cholangiocarcinoma research?
When it comes to advancing treatment options for cholangiocarcinoma, several leading hospitals are at the forefront of groundbreaking clinical trials. In New york City, Memorial Sloan Kettering Cancer Center leads the way with an impressive 13 active trials dedicated to cholangiocarcinoma and a total of 25 completed studies on this rare cancer that affects the bile ducts. Since their first recorded trial in 2000, Memorial Sloan Kettering has been committed to finding new ways to combat this challenging disease. Boston's Massachusetts General Hospital is also making significant contributions in the field with nine ongoing cholangiocarcinoma trials and a history of 19 completed studies since their first trial in 2006.
Heading south to Houston, Texas, The University of Texas MD Anderson Cancer Center is actively conducting eight clinical trials for cholangiocarcinoma and has already accomplished eleven previous investigations since initiating its first trial in 2014. Additionally, there are two other renowned MD Anderson Cancer Centers within Houston which have made notable progress in addressing this condition: one boasts eight ongoing clinical trials with a total of fifteen past investigations dating back to their initial trial in 2011 while another center currently runs six active clinical tests while holding responsibility of previously held sixteen experiments ever conducted; theirs can be traced back only seven years ago since starting their pioneering investigation on such cases.
These esteemed institutions serve as beacons of hope for individuals diagnosed with cholangiocarcinoma and showcase the tireless efforts being made by medical professionals across different locations. Through these collective endeavors, researchers aim not only to improve outcomes for patients but also shed light on new strategies for managing this complex cancer type. Each small step taken through these clinical trials brings us closer to unlocking better treatments and ultimately enhancing the quality of life for those affected by cholangiocarcinoma around the world.
Which are the best cities for cholangiocarcinoma clinical trials?
When it comes to cholangiocarcinoma clinical trials, several cities are at the forefront of research and innovation. Houston, Texas leads with 37 active trials focused on investigating treatments like NGM831, RLY-4008, and NGM438. New york, New York follows closely behind with 32 ongoing studies exploring gavo-cel, LYT-200, and Gemcitabine. Boston, Massachusetts also has 32 active trials examining Cobimetinib, pembrolizumab, and LY3410738. Los Angeles, California and Anchorage Alaska each have 26 active trials exploring various treatment options including Nivolumab and chemotherapy combinations. These cities provide individuals diagnosed with cholangiocarcinoma access to a wide range of cutting-edge clinical trials that hold promise for improved outcomes in the fight against this challenging disease.
Which are the top treatments for cholangiocarcinoma being explored in clinical trials?
Exciting advancements are underway in clinical trials exploring treatments for cholangiocarcinoma. Gemcitabine, a well-established drug since 2002, is currently the frontrunner with five active trials and an impressive track record of 51 all-time cholangiocarcinoma studies. Not far behind is durvalumab, introduced in 2016, which shows promise with two ongoing trials and a total of 16 past cholangiocarcinoma trials. Tivozanib enters the scene more recently in 2021 but has already garnered interest with two active trials dedicated to treating this form of cancer. Lastly, olaparib completes the list by participating in two current studies after its introduction into research for cholangiocarcinoma back in 2019. These developments offer renewed hope to patients battling this challenging disease.
What are the most recent clinical trials for cholangiocarcinoma?
The field of cholangiocarcinoma research is rapidly advancing, with several recent clinical trials offering new hope for patients. Among these trials is the investigation of tinengotinib, an 8 mg QD treatment in Phase 3 that aims to combat this aggressive form of cancer. Additionally, a Phase 2 trial known as Arm A explores potential interventions specifically tailored for cholangiocarcinoma patients. Another promising study combines gemcitabine, cisplatin, durvalumab, and yttrium-90 selective internal radiation therapy to target this challenging disease. Furthermore, significant strides have been made in understanding the role of LSTA1 arm and Cohort 2 (HCC) treatments in advanced head and neck squamous cell carcinoma associated with cholangiocarcinoma. These groundbreaking studies provide renewed optimism for individuals affected by cholangiocarcinoma.
What cholangiocarcinoma clinical trials were recently completed?
Several recent clinical trials have advanced the fight against cholangiocarcinoma, a challenging cancer of the bile ducts. In August 2020, Celldex Therapeutics concluded a trial investigating CDX-527, and in November 2019, the National Cancer Institute completed its study on MVT-5873. Mayo Clinic's trial examining Trifluridine and Tipiracil Hydrochloride wrapped up in October 2019, while another NCI-sponsored trial exploring Mesothelin Expression ended in August of that same year. These trials represent significant efforts to find more effective treatments for cholangiocarcinoma patients and underscore the commitment of researchers in this field.